Table 4.

Responses to therapies of patients with nonmalignant type II mixed cryoglobulinemia.

TreatmentNo. of Therapeutic Sequences (patients)No ResponsePartial ResponseComplete ResponseEarly Relapse or DependenceLate RelapseArrest for Secondary Effects
CS alone14 (12)11101102
CS + AZA2 (2)110101
CS + CYC17 (13)21201104
CS + MMF5 (5)120203
CS + MTX1001000
Interferon-α2200000
  • CS: corticosteroid; AZA: azathioprine; CYC: cyclophosphamide (500–750 mg/m2 intravenous monthly); MMF: mycophenolate mofetil; MTX: methotrexate. Late relapse was defined as occurring at least 3 months after treatment had been stopped. Early relapse was defined as occurring less than 3 months after treatment had been stopped. Dependence was defined as relapse occurring during treatment tapering.